|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Author Index
> Browse Articles > Author Index
Author is indexed since 1999
Author :
Jae Yong Cho
7 Articles
302
ERRATUM: Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor
[Original]
Jang Ho Cho, Jae Yun Lim, Ah Ran Choi, Sung Min Choi, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
Cancer Res Treat.
2018;50(1):302-302. Published online December 6, 2017 DOI:
https://doi.org/10.4143/crt.2013.175.2
Web of Science 1
1196
Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer
So-Young Seol, Chul Kim, Jae Yun Lim, Sun Och Yoon, Soon Won Hong, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
Cancer Res Treat.
2016;48(4):1196-1209. Published online February 26, 2016 DOI:
https://doi.org/10.4143/crt.2015.189
Web of Science 28
Crossref 28
697
Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor
Jang Ho Cho, Jae Yun Lim, Ah Ran Choi, Sung Min Choi, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
Cancer Res Treat.
2015;47(4):697-705. Published online November 27, 2014 DOI:
https://doi.org/10.4143/crt.2013.175
Web of Science 32
Crossref 28
266
Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
Jae Yun Lim, Jang Ho Cho, Se Joon Lee, Dong Ki Lee, Dong Sup Yoon, Jae Yong Cho
Cancer Res Treat.
2015;47(2):266-273. Published online August 29, 2014 DOI:
https://doi.org/10.4143/crt.2013.158
Web of Science 13
Crossref 6
236
Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
Ji Soo Park, Jae Yun Lim, Seung Kyo Park, Min Kyung Kim, Hee Sung Ko, Sun Och Yoon, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
Cancer Res Treat.
2011;43(4):236-243. Published online December 27, 2011 DOI:
https://doi.org/10.4143/crt.2011.43.4.236
Crossref 15
294
Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer
Yoon Jae Kim, Joo Hyuk Sohn, Chul Kim, Yong Tai Kim, Hai Jin Kim, Joong Bae Ahn, Se Kyu Kim, Joon Chang, Nae Choon Yoo, Joo Hang Kim, Jae Yong Cho
Cancer Res Treat.
2003;35(4):294-298. Published online August 31, 2003 DOI:
https://doi.org/10.4143/crt.2003.35.4.294
334
Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer
Chul Kim, Joo Hyuk Sohn, Joo Hang Kim, Se Kyu Kim, Young Sam Kim, Joon Chang, Jae Yong Cho
Cancer Res Treat.
2002;34(5):334-338. Published online October 31, 2002 DOI:
https://doi.org/10.4143/crt.2002.34.5.334
Journal Impact Factor 4.6
> Browse Articles > Author Index
